Gardasil: Not Just for Girls
New research shows young MSMs acquire vaccine-preventable strains of human papillomavirus (HPV) very shortly after becoming sexually active, adding weight to the CDC’s new recommendation that all boys should be vaccinated between the ages of 11 and 12.
A new petition is urging the CDC to recommend the bacterial meningitis vaccine for infants and children. LGBT activists started the petition in response to the recent bacterial meningitis outbreak among men who have sex with men (MSM), arguing that children living in the more than 115,000 same-sex U.S. households should be protected.
After vaccinating 16 rhesus macaque monkeys, the scientists then infected them with a highly aggressive form of SIV. Nine of the monkeys gradually cleared the virus—the first time this feat has ever been achieved in this avenue of HIV study. After the investigators ground up all of the monkeys’ organs and analyzed 240 samples from each to look for virus, finding none, they pronounced the monkeys cured.
NIDA is giving $500,000 a year to these scientists for their work in avant-garde HIV/AIDS research:
Warner Greene is seeking to delay the progression of HIV to AIDS.
Richard Sutton is trying to understand how some people with HIV control the virus without meds.
Timothy Cardozo wants to develop a vaccine that treats both cocaine addiction and prevents HIV.
Strong Support for Vaccinating Young Gay Men for HPV
A syndicate of sexual health physicians have published an editorial in which they spotlight high rates of HPV-related anal disease in gay men and show how the vaccine is both cost-effective and beneficial to public health.
In fact, the CDC is now recommending all 11- and 12-year-old boys receive the vaccination, as well as males up to age 26.
For more information, click here.
…Another HIV Vaccine Trial Shuts Down
In the latest of a string of major setbacks in the search for an HIV vaccine, researchers have shuttered a trial after the experimental vaccine failed to both prevent HIV transmission and to reduce viral load in those who contracted the virus.
Called HVTN 505, the Phase IIb study was conducted by the NIAID-supported HIV Vaccine Trials Network (HVTN). It began in 2009 and enrolled 2,504 men who have sex with men (MSM) and transgendered people who have sex with men in 21 sites in 19 U.S. cities.
To read more, click here.
In Potential Vaccine Breakthrough, Antibody Response Outwits HIV
A new discovery could prove a major stepping-stone toward developing an effective HIV vaccine. In South Africa, two women’s immune systems reacted to changes in HIV cells by producing potent “broadly neutralizing antibodies” that could kill 88 percent of HIV found throughout the world
An experimental therapeutic vaccine helps reduce viral load in people off antiretrovirals for six months. Click here for more.
From the Newsfeed - New Vaccine May Prevent Heroin Highs
Researchers have developed a vaccine that fights heroin highs, and they’ve proved its potential in animal trials, Heroin use and addiction, which costs the United States an estimated $22 billion in losses of productivity, criminal activity, medical care and social welfare, is also a high-risk mode of HIV transmission. The Scripps research team has begun a partnership with Walter Reed Army Institute of Research to examine the feasibility of developing a dual purpose HIV and heroin addiction vaccine. Click here for more.
A vaccine against heroine addiction?? Science blows us away everyday.
From the Newsfeed
The Institute of Human Virology (IHV) at the University of Maryland School of Medicine has received $23.4 million in grants to investigate a vaccine to prevent HIV. Initially developed at IHV, the vaccine is called FLSC (Full-Length Single Chain). It’s designed to invoke immune responses against HIV-1, the most widespread strain of the virus. Click here to read more.